Simone Huber @SimoneHuber2309

𝐅𝐨𝐫𝐦𝐲𝐜𝐨𝐧 𝐁𝐨𝐧𝐝 𝟐𝟎𝟐𝟓/𝟐𝟎𝟐𝟗 𝐬𝐮𝐜𝐜𝐞𝐬𝐬𝐟𝐮𝐥𝐥𝐲 𝐩𝐥𝐚𝐜𝐞𝐝 formycon.com/en/blog/press-…

Happy New Year! 🥂 Welcome to 2025, the year of #quantum! $QBTS

We believe the U.S. government’s efforts to explore near-term quantum computing applications must continue as advanced technologies can address public sector challenges more efficiently. Initiatives aimed at optimizing supply chain management, reinforcing electrical grid…

4.1 million. That's how many problems D-Wave's fast-anneal feature has handled in just 7 months. Check out the whitepaper available now. dwavesys.com/media/x3blg5bk… #QuantumComputing #Optimization #Technology #QuantumAI #Innovation #Productivity #Healthcare #Finance $QBTS

$PLTR @PalantirTech is officially NasdaqListed! @Nasdaq 🥳🎉🍾

Formycon reports nine-month results for 2024 A summary of the operational milestones and financial performance in the first nine months of 2024 can be found in our Corporate News: formycon.com/en/blog/press-…

At home in the strong growth market of biosimilars - and now also in the Prime Standard! This morning on the trading floor of the Frankfurt Stock Exchange, we celebrated the first trading day of Formycon shares in the Prime Standard. formycon.com/en/investor-re…

keyboard_arrow_left Previous keyboard_arrow_right Next

We are deeply grateful to be admitted to the S&P 500. Only in America!

See our full Q2 2024 financial results here: businesswire.com/news/home/2024…

The Dynamic Risk Library, created with Crisis24, provides bespoke, forward-looking intelligence at an unprecedented speed and scope - enabling clients to dominate the security, commodities, insurance, and financial markets.

𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐩𝐡𝐚𝐬𝐞 𝐈𝐈𝐈 𝐭𝐫𝐢𝐚𝐥 𝐭𝐨 𝐜𝐨𝐦𝐩𝐚𝐫𝐞 𝐭𝐡𝐞 𝐬𝐚𝐟𝐞𝐭𝐲 𝐚𝐧𝐝 𝐞𝐟𝐟𝐢𝐜𝐚𝐜𝐲 𝐨𝐟 𝐅𝐘𝐁𝟐𝟎𝟔 𝐰𝐢𝐭𝐡 𝐭𝐡𝐞 𝐢𝐦𝐦𝐮𝐧𝐨-𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐛𝐥𝐨𝐜𝐤𝐛𝐮𝐬𝐭𝐞𝐫 𝐝𝐫𝐮𝐠 𝐊𝐞𝐲𝐭𝐫𝐮𝐝𝐚® 𝐬𝐭𝐚𝐫𝐭𝐞𝐝 formycon.com/en/news-media/…

Curious how the EU Artificial Intelligence Act will foster human-centric and trustworthy #AI adoption, particularly for High-Risk AI Systems? Explore #Palantir's Primer on the EU AI Act, the first installment in our blog series on upcoming AI regulations: blog.palantir.com/a-palantir-pri…

"All of the value in the market is going to go to chips and what we call the Ontology. The Ontology allows you to take an LLM, use it, refine it, and impose it on your enterprise." #Palantir CEO Alex Karp in conversation with @joshuahlipton at #AIPCon: finance.yahoo.com/video/palantir…

Gedeon Richter becomes strategic investor of Formycon formycon.com/en/blog/press-…

Formycon has submitted the biologics license application for its aflibercept #biosimilar candidate #FYB203 to the #FDA Please find our press release here: formycon.com/en/blog/press-… #TeamFormycon #Ophthalmology #nAMD #biotech #Eylea

Last week, #Formycon presented at the #GermanSpringConference in Frankfurt/Main. In our view the presentation confirmed the case: A well-filled product pipeline, financial resources, new management. We reiterate to BUY. bit.ly/3pSa8x8

formycon.com/blog/press-rel…

The European Science & Industry Guide brings together the concentrated expertise of European #biotech companies. We are very pleased that Formycon, as a #biosimilar expert company with its continually growing #development pipeline, is once again part of the 13th Edition.

The value of the global biosimilar market is expected to more than triple by 2030 compared to today's level. McKinsey & Company comes to this forecast in its publication: "Three imperatives for R&D in biosimilars" mckinsey.com/industries/lif…

Klinge Biopharma GmbH, licensee and holder of the worldwide commercialization rights to FYB203, Formycon's biosimilar candidate for Eylea®, has entered into a binding term sheet for the exclusive commercialization of FYB203 in the U.S. with @Coherus_Bio bit.ly/3GRIVnq